Menu

Experience

Kenneth Krisko

    • Poseida Therapeutics Enters Strategic Collaboration and License Agreement With Roche 


    • Immatics Enters Global Exclusive License Agreement With Bristol Myers Squibb 


    • Poseida Therapeutics Enters Research Collaboration With Takeda to Develop Novel Gene Therapies 


    • Merus Enters Collaboration With Eli Lilly to Develop New Generation of Cancer Treatments 


    • Talis Biomedical – $254 Million IPO 


    • Hansa Biopharma Announces Collaboration with Sarepta 


    • Poseida Therapeutics – $224 Million IPO 


    • Therachon Sells to Pfizer for up to $810 Million 


    • Lodo Therapeutics Enters $970 Million Multi-Target Collaboration With Genentech 


    • Selecta Biosciences – $74 Million IPO 


    • AveXis – $95 Million IPO 


    • Cardioxyl Pharmaceuticals sale to Bristol-Myers Squibb 


    • NewLink Will License Ebola Vaccine to Merck 


    • FORMA $600 Million Collaboration with Celgene 


    • TYRX: Acquired by Medtronic 


    • Two Independent Billion-Dollar Life Sciences Collaborations 


    • Apollo Endosurgery Agreement Acquire Obesity Intervention Division of Allergan 


    • FORMA Therapeutics $200M Strategic Collaboration Deal with Celgene 


    • Cylex Use Chapter 11 Bankruptcy to Achieve Exceptional Sale Price